E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Adrenomyeloneuropathy |
Adrenomieloneuropatía |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nervous System Diseases [C10] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 17.0 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10069075 |
E.1.2 | Term | Adrenomyeloneuropathy without cerebral involvement |
E.1.2 | System Organ Class | 100000004850 |
|
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To demonstrate the superiority of MD1003 (biotin) at 300 mg/day over placebo in the clinical improvement of patients with Adrenomyeloneuropathy |
Demostrar la mayor eficacia de MD1003 respecto del placebo para la mejora clínica de pacientes con AMN. |
|
E.2.2 | Secondary objectives of the trial |
To evaluate safety of MD1003 in patients with Adrenomyeloneuropathy |
Evaluar la seguridad de MD1003 en el tratamiento de la AMN. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Men of 18 to 60 years old, inclusive - ABCD1 gene mutation identified - Elevated plasma VLCFA - Clinical signs of AMN with at least pyramidal signs in the lower limbs and difficulties to walk - EDSS score ? 3.5 and ? 6.5 - Normal brain MRI or brain MRI showing : - abnormalities that can be observed in AMN patients without cerebral demyelination with a maximum Loes score of 4 - and/or stable (?6 months) cerebral demyelination without gadolinium enhancement with a Loes score ?12. - Appropriate steroid replacement if adrenal insufficiency is present - Likely to be able to participate in all scheduled evaluation visits and complete all required study procedures - Signed and dated written informed consent to participate in the study in accordance with local regulations - Affiliated to a Health Insurance |
° Hombres de 18 a 60 años con AMN: - mutación de ABCD1 identificada; - elevadas concentraciones plasmáticas de AGCML (ácidos grasos de cadena muy larga). ° Signos clínicos de AMN con al menos un síndrome del piramidal en las extremidades inferiores y dificultad para caminar. ° Puntuación de entre 3,5 y 6,5 en la escala EDSS (Escala Expandida del Estado de Discapacidad). ° IRM cerebral normal o IRM cerebral que muestre: (a) anomalías que pudiera observarse en pacientes con AMN sin desmielinización cerebral y con puntuación máxima de 4 en la escala de Loes; y/o (b) desmielinización estable (≥ 6 meses) sin captación de gadolinio con puntuación ≤ 12 en la escala de Loes. ° Sustitución adaptada con esteroides en caso de insuficiencia surrenal. ° Capacidad de realizar todas las evaluaciones previstas. ° Firma del consentimiento informado. |
|
E.4 | Principal exclusion criteria |
- Brain MRI abnormalities with a Loes score > 12 or with gadolinium enhacement - Any progressive neurological disease other than AMN - Impossibility to perform the walk tests and the TUG test - Patients with uncontrolled hepatic disorder, renal or cardiovascular disease, or any evolutive malignancy - Any new medication for AMN including Fampridine initiated less than 1 month prior to inclusion - Contraindications for MRI procedure such as subjects with paramagnetic materials in the body, such as aneurysm clips, pacemakers, intraocular metal or cochlear implants. - Inclusion in another therapeutic clinical trial for ALD - Patient not easily reachable by the investigator in case of emergency or not capable to call the investigator |
° IRM cerebral anómala con puntuación en la escala de Loes > 12 o con captación de gadolinio. ° Cualquier neuropatía distinta de la AMN. ° Incapacidad de realizar las pruebas de marcha y la prueba funcional de TUG. ° Enfermedad hepática, renal o cardiovascular, o cualquier patología maligna evolutiva. ° Cualquier nuevo tratamiento para la AMN en que se haya iniciado la administración de fampridina menos de un mes antes de la inclusión. ° Pacientes en que la IRM esté contraindicada. ° Inclusión en otro ensayo para el tratamiento de la AMN. ° Difícil acceso al investigador en caso de urgencia o imposibilidad de acudir al investigador durante el estudio en general. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Mean change of 2 minutes walking test (2MWT) between M12 and baseline |
variación de 2 minutos en la prueba de M12 respecto del valor inicial. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
Baseline, 12 months, 24 months |
Valor inicial, 12 meses y 24 meses |
|
E.5.2 | Secondary end point(s) |
- Proportion of patients with improved 2-Minutes-Walk-Tests (2MWT) of at least 20% at M9 and M12 compared to the best value among screening and baseline? - Proportion of patients with improved TW25 (time to walk 25 feet) of at least 20% at M9 and M12 compared to the best value among screening and baseline - Timed up and Go test (TUG) - Euroqol EQ-5D questionnaire - Qualiveen to evaluate urinary function - To evaluate the safety of high dose of biotin assessed by: adverse events, clinical examination (vital signs, ECG), standard laboratory tests (hematology, biochemistry) Exploratory studies (optional): 1) Brain MRI with conventional and non conventional sequences: a) diffusion tensor imaging (DTI) parameters in the upper cervical spinal cord and brain; b) magnetic resonance spectroscopy (MRS) in the cerebral white matter. 2) Evaluation of muscle strength by the use of a dynamometer 3) Nerve conduction velocities in lower limbs (NCV) |
- Proporción de pacientes que presente una mejora del 20 % en la 2MWT (prueba de marcha 2 min) de M12 respecto de la de M9 - Proporción de pacientes que presente una mejora del 20 % en la TW25 (prueba cronometrada de marcha de 25 pies) de M12 respecto de la de M9 - Prueba TUG cronometrada - Cuestionario Euroqol EQ-5D - Cuestionario Qualiveen (función urinaria) - Evaluación de la tolerancia a dosis elevadas de biotina: acontecimientos adversos, examen clínico (constantes vitales, ECG), análisis biológicos estándar (hematología y bioquímica) Criterios de exploración (optativos): 1) IRM cerebral: a) IRM convencional; b) Imagen por tensor de difusión (ITD) cerebral y medular; c) Espectroscopia por resonancia magnética (ERM) de la sustancia blanca del cerebral. 2) Evaluación de la fuerza muscular mediante dinamómetro. 3) Velocidad de conducción nerviosa (VCN) de las extremidades inferiores. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
Baseline, 9 months, 12 months, 18 months, 24 months |
Valor inicial, 9 meses, 12 meses, 18 meses y 24 meses |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | Yes |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 2 |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 2 |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.5.1 | Number of sites anticipated in the EEA | 4 |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
Last visit of the last patient |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 2 |